BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

Inclusion Criteria:

   - Be ≥ 18 years of age

   - Have a life expectancy ≥ 6 weeks

   - Have a Karnofsky Performance Score (KPS) ≥ 60

   - Have pathologically proven GB, gliosarcoma (WHO IV), or anaplastic astrocytoma (WHO
   III) in recurrence after treatment with bevacizumab

   - Be at least 14 days from the last administration of bevacizumab

   - Be at least 28 days from last administration of cytotoxic chemotherapy or other
   investigational agent

   - Have received radiation therapy with concurrent temozolomide. Total radiation dosage
   can range from 5400 to 6000 cGy administered in daily fractions of 150 to 200 cGy over
   6 weeks, or the equivalent in a hypofractionated protocol (for example, 4000cGy in 15
   fractions or 2500cGy in 5 fractions). Patients who are MGMT negative do not need to
   have received temozolomide.

   - Have adequate organ and marrow function as follows (all required):

      - ANC ≥ 1500 mm3

      - Platelets ≥ 100,000/mm3

      - Hemoglobin ≥ 9 g/dL

      - Serum creatinine ≤ 1.8 mg/dL or creatinine clearance > 50 mL/min Bilirubin ≤ 1.5
      mg/dL

      - Alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)

      - Aspartate transaminase (AST) ≤ 2.5 x ULN

      - Prothrombin time (PT) ≤ 1.5 x ULN

      - International Normalized Ratio (INR) ≤ 1.5 x ULN

      - Partial thromboplastin time (PTT) ≤ 1.5 x ULN

   - Subjects of childbearing potential must agree to use hormonal or barrier birth control
   with spermicidal gel to avoid pregnancy during the study

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Has a history of spontaneous or tumor related cerebral hemorrhage; or has cerebral
   hemorrhage as determined by the screening FDG PET CT and MRI. This does not include
   stable post operative blood products seen on a gradient echo MRI sequence.

   - Has the any of the following cardiac history:

      - Active heart disease including myocardial infarction within previous 3 months

      - Symptomatic coronary artery disease

      - Arrhythmias not controlled by medication

      - Unstable angina pectoris

      - Uncontrolled or symptomatic congestive heart failure (NYHA class III and IV)
      3.2.3 Uncontrolled or severe coagulopathies or a history of clinically
      significant bleeding within the past 6 months, including any of the following,
      but not limited to:

      - Epistaxis

      - Hemoptysis

      - Hematochezia

      - Hematuria

      - Gastrointestinal bleeding

      - Spontaneous or tumor related intracranial hemorrhage

   - Known predisposition for bleeding such as von Willebrand's disease or other such
   condition(s)

   - Uncontrolled concurrent illness that would limit compliance with study requirements,
   including any of the following, but limited to:

      - Uncontrolled infection.

      - Psychiatric illness/social situations

   - Prior malignancy except for non melanoma skin cancer and carcinoma in situ (of the
   cervix or bladder), unless diagnosed and definitively treated more than 3 years prior
   to 1st dose of investigational drug

   - Receiving any of the following medications:

      - Therapeutic doses of any anticoagulant, including low molecular weight heparin
      (LMWH). Concomitant use of warfarin, even at prophylactic doses, is prohibited

      - Digoxin, digitoxin, lanatoside C, or any type of digitalis alkaloids.

      - Colony stimulating factors (CSFs) that cannot be held during the monitoring
      period for dose limiting toxicities (DLT)

   - Has significant toxicities from prior treatment that have not resolved or stabilized

   - Known allergy to Coenzyme Q10

   - Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K

   - Is pregnant or lactating

   - Known to be positive for the human immunodeficiency virus (HIV). Note: HIV testing is
   not required for eligibility, but if performed previously and was positive, the
   subject is ineligible.